Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2019001416) THIAZOLINONE HETEROCYCLIC COMPOUND AND PREPARATION METHOD, PHARMACEUTICAL COMPOSITION, AND APPLICATION THEREOF
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2019/001416 International Application No.: PCT/CN2018/092824
Publication Date: 03.01.2019 International Filing Date: 26.06.2018
IPC:
C07D 277/36 (2006.01) ,C07D 417/10 (2006.01) ,C07D 417/06 (2006.01) ,C07D 417/14 (2006.01) ,A61K 31/426 (2006.01) ,A61K 31/427 (2006.01) ,A61P 35/00 (2006.01) ,A61P 1/06 (2006.01) ,A61P 3/04 (2006.01) ,A61P 9/00 (2006.01) ,A61P 25/00 (2006.01) ,A61P 29/00 (2006.01)
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
277
Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
02
not condensed with other rings
20
having two or three double bonds between ring members or between ring members and non-ring members
32
with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
36
Sulfur atoms
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
417
Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/196
02
containing two hetero rings
10
linked by a carbon chain containing aromatic rings
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
417
Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/196
02
containing two hetero rings
06
linked by a carbon chain containing only aliphatic carbon atoms
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
417
Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/196
14
containing three or more hetero rings
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
41
having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole
425
Thiazoles
426
1,3-Thiazoles
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
41
having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole
425
Thiazoles
427
not condensed and containing further heterocyclic rings
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35
Antineoplastic agents
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
1
Drugs for disorders of the alimentary tract or the digestive system
06
Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
3
Drugs for disorders of the metabolism
04
Anorexiants; Antiobesity agents
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
9
Drugs for disorders of the cardiovascular system
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
25
Drugs for disorders of the nervous system
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
29
Non-central analgesic, antipyretic or antiinflammatory agents, e.g antirheumatic agents; Non-steroidal antiinflammatory drugs (NSAIDs)
Applicants:
中国科学技术大学 UNIVERSITY OF SCIENCE AND TECHNOLOGY OF CHINA [CN/CN]; 中国安徽省合肥市 金寨路96号 No.96 JinZhai Road Baohe District Hefei, Anhui 230026, CN
Inventors:
周荣斌 ZHOU, Rongbin; CN
邓贤明 DENG, Xianming; CN
江维 JIANG, Wei; CN
姜华 JIANG, Hua; CN
陈云 CHEN, Yun; CN
Agent:
北京集佳知识产权代理有限公司 UNITALEN ATTORNEYS AT LAW; 中国北京市 朝阳区建国门外大街22号赛特广场7层 7th Floor, Scitech Place No.22, Jian Guo Men Wai Ave., Chao Yang District Beijing 100004, CN
Priority Data:
201710494473.526.06.2017CN
Title (EN) THIAZOLINONE HETEROCYCLIC COMPOUND AND PREPARATION METHOD, PHARMACEUTICAL COMPOSITION, AND APPLICATION THEREOF
(FR) COMPOSÉ HÉTÉROCYCLIQUE DE THIAZOLINONE, PROCÉDÉ DE PRÉPARATION, COMPOSITION PHARMACEUTIQUE ET APPLICATION DE CELUI-CI
(ZH) 噻唑啉酮杂环化合物、其制备方法、药用组合物及应用
Abstract:
(EN) The present invention provides a thiazolinone heterocyclic compound and a preparation method, pharmaceutical composition, and application thereof. The present invention provides an application of the thiazolinone heterocyclic compound in preparing an NLRP3 Inflammasome inhibitor. The thiazolinone heterocyclic compound has a structure of formulas I or II or an isomer, prodrug, or pharmaceutically acceptable solvate or salt thereof: (I), (II)
(FR) La présente invention concerne un composé hétérocyclique de thiazolinone et un procédé de préparation de celui-ci, une composition pharmaceutique et une application correspondantes. La présente invention concerne une application du composé hétérocyclique de thiazolinone dans la préparation d'un inhibiteur de l'inflammasome NLRP3. Le composé hétérocyclique de thiazolinone a une structure des formules I ou II ou un isomère, un promédicament, ou un solvate ou un sel pharmaceutiquement acceptable de celui-ci : (I), (II)
(ZH) 本发明提供了一种噻唑啉酮杂环化合物、其制备方法、药用组合物及应用,其中,本发明提供了噻唑啉酮杂环化合物在制备 NLRP3 炎症小体抑制剂中的应用,所述噻唑啉酮杂环化合物具有式Ⅰ或式Ⅱ所示结构或其异构体、前药、药学上可接受的溶剂化物或盐:(I), (II)
front page image
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: Chinese (ZH)
Filing Language: Chinese (ZH)